Upfront identification of high‐risk follicular lymphoma
Author:
Open Access
- 9 June 2021
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 39 (S1) , 88-93
Abstract
Follicular lymphoma (FL) is a common disease with clinically indolent behavior, and a long natural history for the majority of patients. Despite excellent therapeutic strategies currently available for FL, approximately 10%–20% of patients will experience early disease progression, defined as occurring within two years of diagnosis. These patients have poor outcomes, with overall survival at 5 years ranging between 37% and 50%. Much of the biology driving early progression and inferior survival is attributed to early transformation events; however, transformation alone does not account for all the observed clinical heterogeneity and survival differences among patients. Several clinical, genetic, and molecular alterations in FL have been discovered that help define subsets of patients at risk for multiply relapses and refractory disease, and are slowly making their way into risk calculators to be used in daily practice. Additionally, the role of functional imaging with PET scan, as well as circulating and cell free tumor DNA are being evaluated as tools to define high-risk subsets of patients with FL. This review seeks to provide an over view of current and evolving biomarkers that define high-risk FL at diagnosis. The goal is for these tools to assist clinicians in integrating these rapidly evolving prognosis models into clinical practice, in the hopes of risk-stratifying treatments and improving outcomes for patients.Keywords
This publication has 13 references indexed in Scilit:
- Follicular LymphomaHematology/Oncology Clinics of North America, 2019
- Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphomaBlood Advances, 2018
- Unmet needs in the first-line treatment of follicular lymphomaAnnals of Oncology, 2017
- Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter StudiesJournal of Clinical Oncology, 2016
- 2016 US lymphoid malignancy statistics by World Health Organization subtypesCA: A Cancer Journal for Clinicians, 2016
- Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare StudyAnnals of Oncology, 2015
- Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practicesAnnals of Oncology, 2012
- Cancer biomarkersMolecular Oncology, 2012
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor ProjectJournal of Clinical Oncology, 2009
- Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune CellsNew England Journal of Medicine, 2004